Method of stimulating an immune response using a pseudotyped lentivirus
US-9303072-B2 · Apr 5, 2016 · US
Recombinant retrovirus pseudotyped with E2 alphavirus glycoprotein
US9840721B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9840721-B2 |
| Application number | US-201615051907-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 24, 2016 |
| Priority date | Jul 21, 2006 |
| Publication date | Dec 12, 2017 |
| Grant date | Dec 12, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.
First claim
Opening claim text (preview).
What is claimed is: 1. A recombinant replication deficient lentivirus pseudotyped with a modified alphavirus E2 glycoprotein that more efficiently transduces dendritic cells compared to other cell types; wherein the lentivirus comprises an exogenous polynucleotide of interest. 2. The recombinant lentivirus of claim 1 , wherein the recombinant lentivirus comprises an inactivated or self-inactivating 3′ LTR. 3. The recombinant lentivirus of claim 1 further pseudotyped with an E1 alphavirus glycoprotein. 4. The recombinant lentivirus of claim 1 wherein the lentivirus is a human immunodeficiency virus (HIV), murine stem cell virus (MSCV), or murine leukemia virus (MLV). 5. The recombinant lentivirus of claim 1 wherein the polynucleotide of interest encodes a protein selected from the group consisting of GM-CSF, IL-2, IL-4, IL-6, IL-7, IL-15, IL-21, IL-23, TNFα, B7.1, B7.2, 4-1BB, CD40 ligand (CD40L) and drug-inducible CD40 (iCD40). 6. The recombinant lentivirus of claim 1 wherein the alphavirus E2 glycoprotein is a Sindbis virus E2 glycoprotein. 7. The recombinant lentivirus of claim 6 wherein the lentivirus is a human immunodeficiency virus (HIV), murine stem cell virus (MSCV), or murine leukemia virus (MLV).
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9840721B2 cover?
- Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.
- Who is the assignee on this patent?
- California Inst Of Techn
- What technology area does this patent fall under?
- Primary CPC classification C12N15/86. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).